Adverse Events Associated With Proton Pump Inhibitors: Fact Vs Fiction
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Moayyedi P, Eikelboom J, Bosch J, Connolly S, Dyal L, Shestakovska O
. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019; 157(3):682-691.e2.
DOI: 10.1053/j.gastro.2019.05.056.
View
2.
Laheij R, Sturkenboom M, Hassing R, Dieleman J, Stricker B, Jansen J
. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004; 292(16):1955-60.
DOI: 10.1001/jama.292.16.1955.
View
3.
Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid F
. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017; 63(5):354-364.
PMC: 5429051.
View
4.
Moayyedi P, Lacy B, Andrews C, Enns R, Howden C, Vakil N
. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017; 112(7):988-1013.
DOI: 10.1038/ajg.2017.154.
View
5.
Eikelboom J, Connolly S, Bosch J, Dagenais G, Hart R, Shestakovska O
. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14):1319-1330.
DOI: 10.1056/NEJMoa1709118.
View